About Altoida
Altoida is a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive and functional impairment, symptomatic deficits due to amyloid pathology, and potential progression to Alzheimer’s disease. We are relentlessly driven by the goal of enabling earlier diagnosis, accelerated patient inclusion into clinical trials, as well as sensitive monitoring of disease progression and treatment response.
Our mission is to unleash the power of digital biomarkers to ignite an era of precision neurology. Our proprietary evidence-based platform is founded on more than 20 years of scientific research. Our technology has been published in multiple peer-reviewed journals, including Nature Digital Medicine and Alzheimers & Dementia.
Our technology platform can potentially be leveraged as an objective measure of cognitive and functional performance across a broad expanse of neurological clinical trials, providing timely insight to our partners to better understand baseline measures of cognition, and hopefully improve clinical trial outcomes by providing real-time insights into a study participant’s disease progression.
We envision a future with precision brain diagnosis at scale to transform neurological care, enable faster clinical trials, greater access to breakthrough treatments, and to enable earlier decision-making for patients and their loved ones.
Our platform is currently intended for investigational use only. The platform has not received FDA clearance or approval and is not available for commercial sale.
Our mission is to unleash the power of digital biomarkers to ignite an era of precision neurology. Our proprietary evidence-based platform is founded on more than 20 years of scientific research. Our technology has been published in multiple peer-reviewed journals, including Nature Digital Medicine and Alzheimers & Dementia.
Our technology platform can potentially be leveraged as an objective measure of cognitive and functional performance across a broad expanse of neurological clinical trials, providing timely insight to our partners to better understand baseline measures of cognition, and hopefully improve clinical trial outcomes by providing real-time insights into a study participant’s disease progression.
We envision a future with precision brain diagnosis at scale to transform neurological care, enable faster clinical trials, greater access to breakthrough treatments, and to enable earlier decision-making for patients and their loved ones.
Our platform is currently intended for investigational use only. The platform has not received FDA clearance or approval and is not available for commercial sale.